Skip to main content
Premium Trial:

Request an Annual Quote

Genzyme Molecular Licenses Rights to Affymetrix

Premium

Genzyme Molecular Oncology of Framingham, Mass., has exclusively licensed certain high density DNA array diagnostic and research rights related to the p53 gene to Affymetrix for use on its GeneChip arrays.

Affymetrix currently sells p53 arrays that analyze the coding region of the p53 tumor suppressor gene.

In exchange for exclusive rights to p53 for use on certain diagnostic and research DNA arrays, Genzyme Molecular Oncology will receive from Affymetrix an up-front payment of an undisclosed amount, milestones, and minimum royalties on the sale of future GeneChip products that utilize the p53 gene.

The Affymetrix license will allow GeneChip array customers to conduct microarray-based p53 tests without seeking an additional license from Genzyme.

The p53 gene functions as a tumor suppressor in the human body. Studies have shown that in more than 50 percent of all human cancers the p53 gene is mutated, Genzyme said.

Filed under

The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.